Teva Pharmaceuticals in peer group American glamour stocks

Share Teva Pharmaceuticals among the losing American glamour stocks

The Teva Pharmaceuticals share now belongs to the worse performing glamour stocks in US. Over the past 12 months the glamour stock is an impressive 27 percent lower. The American glamour stocks are 128 percent lower. For a Teva Pharmaceuticals share now 8 times the CAPE-ratio is paid. The average American glamour stocks are traded at 7.

For this year Teva Pharmaceuticals's revenue will be around 18,99 billion USD. This is according to the average of the analysts' estimates. This is quite lower than 2017's revenue of 22,39 billion USD.

Historical revenues and results Teva Pharmaceuticals plus estimates 2018

The analysts expect for 2018 a net profit of 2,81 billion USD. For this year the consensus of Teva Pharmaceuticals's result per share is a profit of 2,69 USD. The price/earnings-ratio is then 9,04.

Analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies equals a limited 0,5 percent.

Most recent target prices around 18 USD

The most recent recommendations for the pharmaceutical company are from Credit Suisse , JP Morgan and KBC Securities.

Based on the current number of shares Teva Pharmaceuticals's market capitalization equals 24,68 billion USD.

Historical stock prices Teva Pharmaceuticals2007-2018

On Friday, the stock closed at 24,32 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.